Eloxx Pharmaceuticals (ELOX) Financials

Eloxx Pharmaceuticals logo
$11.00 +0.59 (+5.67%)
As of 01:42 PM Eastern
Annual Income Statements for Eloxx Pharmaceuticals

Annual Income Statements for Eloxx Pharmaceuticals

This table shows Eloxx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-19 -8.45 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Consolidated Net Income / (Loss)
-18 -8.27 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Net Income / (Loss) Continuing Operations
-18 -8.27 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Total Pre-Tax Income
-18 -8.95 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Total Operating Income
-18 -11 -20 -48 -51 -33 -66 -34 -17 -2.47 -6.44
Total Gross Profit
0.08 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.36 0.00
Total Revenue
0.08 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.36 0.00
Operating Revenue
0.08 0.08 - - - - - - 0.00 6.36 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
18 11 20 48 51 33 66 34 17 8.83 6.44
Selling, General & Admin Expense
3.17 1.61 2.70 26 24 15 20 11 8.69 5.25 3.38
Research & Development Expense
4.57 2.18 16 20 26 15 46 24 8.60 3.58 3.06
Total Other Income / (Expense), net
0.01 2.25 -0.82 0.50 -0.32 -1.12 -0.71 -1.65 0.23 -0.68 0.44
Other Income / (Expense), net
0.02 2.25 -0.82 0.50 -0.32 -1.12 -0.71 -1.65 0.23 -0.68 0.44
Basic Earnings per Share
($1.31) ($0.42) ($4.75) ($1.45) ($1.34) ($0.86) ($38.15) ($16.65) ($6.63) ($0.84) ($0.49)
Weighted Average Basic Shares Outstanding
14.42M 20.32M 4.98M 32.44M 38.06M 40.12M 1.75M 2.17M 2.57M 3.76M 12.35M
Diluted Earnings per Share
($1.31) ($0.42) ($4.75) ($1.45) ($1.34) ($0.86) ($38.15) ($16.65) ($6.63) ($0.84) ($0.49)
Weighted Average Diluted Shares Outstanding
14.42M 20.32M 4.98M 32.44M 38.06M 40.12M 1.75M 2.17M 2.57M 3.76M 12.35M
Weighted Average Basic & Diluted Shares Outstanding
14.42M 20.32M 4.98M 32.44M 38.06M 40.12M 69.96M 2.17M - - 5.07M

Quarterly Income Statements for Eloxx Pharmaceuticals

This table shows Eloxx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Consolidated Net Income / (Loss)
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Net Income / (Loss) Continuing Operations
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Total Pre-Tax Income
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Total Operating Income
-3.64 -4.03 -1.22 -1.58 -0.29 -3.80 -4.45 -5.95
Total Gross Profit
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
3.64 4.03 1.22 1.58 0.29 3.80 4.45 5.95
Selling, General & Admin Expense
2.39 2.51 0.71 0.68 0.54 2.14 1.61 1.93
Research & Development Expense
1.25 1.52 0.51 0.90 -0.25 1.66 2.84 4.03
Total Other Income / (Expense), net
0.05 1.14 -0.49 -0.31 -0.07 0.04 -0.05 0.41
Other Income / (Expense), net
0.05 1.14 -0.49 -0.31 -0.07 0.04 -0.05 0.41
Basic Earnings per Share
($1.31) ($0.48) ($0.45) ($5.45) ($0.58) ($0.08) ($0.66) ($0.49)
Weighted Average Basic Shares Outstanding
2.75M 2.57M 3.81M 347K 604.28K 48.21M 6.79M 11.40M
Diluted Earnings per Share
($1.31) ($0.48) ($0.45) ($5.45) ($0.58) ($0.08) ($0.66) ($0.49)
Weighted Average Diluted Shares Outstanding
2.75M 2.57M 3.81M 347K 604.28K 48.21M 6.79M 11.40M
Weighted Average Basic & Diluted Shares Outstanding
3.14M 0.00 - - - 7.57M 4.04M 4.09M

Annual Cash Flow Statements for Eloxx Pharmaceuticals

This table details how cash moves in and out of Eloxx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-2.78 -2.52 22 25 -26 2.19 18 -23 -18 -1.24 4.68
Net Cash From Operating Activities
-7.34 -3.68 -16 -31 -39 -28 -35 -32 -14 -4.72 -6.33
Net Cash From Continuing Operating Activities
-7.34 -3.68 -16 -31 -39 -28 -35 -32 -14 -4.72 -6.33
Net Income / (Loss) Continuing Operations
-18 -8.27 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Consolidated Net Income / (Loss)
-18 -8.27 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Depreciation Expense
0.18 0.09 0.04 0.22 0.09 0.07 0.11 0.08 0.11 0.04 0.00
Amortization Expense
- - 0.67 0.00 0.71 1.08 1.27 1.16 0.96 0.60 0.25
Non-Cash Adjustments To Reconcile Net Income
12 5.33 3.52 13 11 8.67 30 3.10 0.80 -1.70 1.87
Changes in Operating Assets and Liabilities, net
-1.10 -0.83 1.06 2.22 -0.64 -3.40 -0.03 -0.12 0.80 -0.51 -2.45
Net Cash From Investing Activities
-0.26 0.00 -0.11 -0.32 -34 34 2.06 -0.07 0.31 0.04 0.00
Net Cash From Continuing Investing Activities
-0.26 0.00 -0.11 -0.32 -34 34 2.06 -0.07 0.31 0.04 0.00
Sale of Property, Plant & Equipment
- - 0.00 0.01 0.00 0.00 0.00 0.00 0.31 0.04 0.00
Net Cash From Financing Activities
4.83 1.15 38 56 47 -3.44 51 8.81 -4.08 3.44 11
Net Cash From Continuing Financing Activities
4.83 1.15 38 56 47 -3.44 51 8.81 -4.08 3.44 11
Repayment of Debt
- - 0.00 0.00 -0.28 -4.58 -11 0.00 -9.40 -0.61 -1.26
Issuance of Debt
0.00 0.00 2.50 0.00 15 0.80 12 0.00 0.00 3.67 2.87
Issuance of Common Equity
4.83 1.15 17 2.17 33 0.00 48 0.00 4.89 0.00 9.69
Other Financing Activities, net
- - 0.02 54 -0.81 0.35 2.58 8.81 0.43 0.38 -0.30
Cash Interest Paid
0.00 0.00 0.00 0.00 0.99 0.83 0.73 1.37 0.99 0.14 0.03
Cash Income Taxes Paid
- - 0.00 0.00 0.04 0.01 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Eloxx Pharmaceuticals

This table details how cash moves in and out of Eloxx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
0.45 -3.64 0.34 0.12 3.64 1.58 56 -5.70
Net Cash From Operating Activities
-3.45 -2.01 1.20 -1.75 -1.72 -5.45 -4.79 -4.28
Net Cash From Continuing Operating Activities
-3.45 -2.06 1.20 -1.75 -1.72 -5.45 -4.79 -4.28
Net Income / (Loss) Continuing Operations
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Consolidated Net Income / (Loss)
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Amortization Expense
0.23 0.22 0.24 - 0.00 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income
0.15 -0.98 2.40 0.13 -0.13 -0.01 0.16 0.23
Changes in Operating Assets and Liabilities, net
-0.25 1.52 0.27 0.01 -1.24 -1.70 -0.45 1.03
Net Cash From Financing Activities
3.67 -1.68 -0.87 1.88 5.35 7.03 60 -1.42
Net Cash From Continuing Financing Activities
3.67 -1.68 -0.87 1.88 5.35 7.03 60 -1.42
Issuance of Debt
- - 0.39 1.88 0.60 0.00 6.99 -6.99
Issuance of Common Equity
3.46 0.00 - - 4.75 6.99 53 5.57

Annual Balance Sheets for Eloxx Pharmaceuticals

This table presents Eloxx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
20 9.23 25 51 59 26 45 21 1.71 2.98 5.27
Total Current Assets
3.73 0.98 25 50 58 26 43 20 1.55 2.98 5.27
Cash & Equivalents
3.33 0.81 24 49 22 25 42 19 1.13 0.11 4.79
Restricted Cash
- - 0.10 0.05 0.04 0.06 0.30 0.26 0.22 0.01 0.01
Prepaid Expenses
0.40 0.17 0.36 1.69 1.39 1.17 0.91 0.66 0.19 0.14 0.48
Plant, Property, & Equipment, net
0.19 0.09 0.28 0.25 0.20 0.13 0.22 0.17 0.04 0.00 0.00
Total Noncurrent Assets
16 8.15 0.00 0.13 1.04 0.45 1.44 0.83 0.13 0.00 0.00
Total Liabilities & Shareholders' Equity
20 9.23 25 51 59 26 45 21 1.71 2.98 5.27
Total Liabilities
7.32 4.67 3.42 7.81 23 16 23 32 24 27 17
Total Current Liabilities
0.78 0.37 3.42 7.81 12 9.84 9.96 23 23 27 17
Short-Term Debt
- 0.00 - 0.00 4.34 5.24 0.00 3.98 2.22 6.52 1.00
Accounts Payable
0.23 0.09 1.53 0.75 1.87 0.48 1.38 3.02 5.70 5.35 2.71
Accrued Expenses
0.41 0.26 1.89 6.94 4.66 2.92 4.20 2.80 1.16 1.45 1.61
Other Current Liabilities
0.14 0.02 - 0.00 0.90 1.19 4.38 13 14 13 12
Other Current Nonoperating Liabilities
- - - - - - - - 0.05 0.56 0.04
Total Noncurrent Liabilities
6.54 4.30 0.00 0.00 11 6.41 13 8.69 1.61 0.00 0.00
Commitments & Contingencies
- - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
12 4.56 21 43 36 10 22 -11 -23 -24 -12
Total Preferred & Common Equity
12 4.56 21 43 36 10 22 -11 -23 -24 -12
Preferred Stock
- - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
12 4.56 21 43 36 10 22 -11 -23 -24 -12
Common Stock
119 120 60 130 175 184 263 264 269 270 289
Retained Earnings
-107 -116 -39 -86 -137 -172 -238 -274 -291 -295 -301

Quarterly Balance Sheets for Eloxx Pharmaceuticals

This table presents Eloxx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2026 6/30/2026 9/30/2026
Total Assets
6.04 8.50 63 58
Total Current Assets
5.63 8.50 63 58
Cash & Equivalents
4.78 6.36 62 56
Restricted Cash
0.22 0.01 0.01 0.01
Prepaid Expenses
0.64 2.13 1.42 1.99
Plant, Property, & Equipment, net
0.11 0.00 0.00 0.00
Total Noncurrent Assets
0.31 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
6.04 8.50 63 58
Total Liabilities
26 16 17 17
Total Current Liabilities
23 16 17 17
Short-Term Debt
2.82 0.00 0.00 0.00
Accounts Payable
3.13 3.03 3.03 2.42
Accrued Expenses
2.44 1.24 2.05 2.83
Other Current Liabilities
15 12 12 12
Other Current Nonoperating Liabilities
- 0.00 0.00 0.00
Total Noncurrent Liabilities
2.62 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-20 -7.58 46 41
Total Preferred & Common Equity
-20 -7.58 46 41
Preferred Stock
0.00 0.00 0.00 0.00
Total Common Equity
-20 -7.58 46 41
Common Stock
269 297 355 355
Retained Earnings
-289 -304 -309 -314

Annual Metrics And Ratios for Eloxx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eloxx Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
16,387,522.00 20,420,608.00 27,527,738.00 35,860,114.00 40,002,654.00 40,152,883.00 86,252,365.00 86,656,221.00 3,143,390.00 3,143,390.00 3,143,390.00
DEI Adjusted Shares Outstanding
16,387,522.00 20,420,608.00 27,527,738.00 35,860,114.00 40,002,654.00 40,152,883.00 86,252,365.00 86,656,221.00 3,143,390.00 3,143,390.00 3,143,390.00
DEI Earnings Per Adjusted Shares Outstanding
-1.15 -0.41 -0.77 -1.32 -1.27 -0.86 -0.77 -0.42 -5.43 -1.00 -1.91
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-25.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth
-103.27% 50.49% -131.61% -266.45% -6.90% 33.25% -95.49% 46.70% 54.10% 84.29% -128.99%
EBIT Growth
-97.44% 50.46% -137.10% -252.66% -8.10% 32.03% -92.98% 45.95% 52.71% 81.57% -90.74%
NOPAT Growth
-97.61% 38.07% -82.14% -196.57% -6.29% 33.82% -97.33% 47.86% 49.77% 85.72% -160.86%
Net Income Growth
-95.81% 54.23% -156.58% -122.42% -7.82% 32.03% -92.98% 45.95% 52.71% 81.57% -90.74%
EPS Growth
48.22% 67.94% -1,030.95% 69.47% 7.59% 35.82% -4,336.05% 56.36% 60.18% 87.33% 41.67%
Operating Cash Flow Growth
-50.87% 49.95% -333.46% -96.84% -25.58% 28.50% -24.27% 9.02% 54.97% 67.12% -34.19%
Free Cash Flow Firm Growth
99.29% -1,531.13% -186.82% -452.95% -18.17% 28.03% -58.50% 64.09% 34.52% 54.01% -40.65%
Invested Capital Growth
-58.42% -57.82% -174.40% -5.73% 8.22% 45.35% -184.37% -114.87% -14.12% 13.43% 9.87%
Revenue Q/Q Growth
100.00% -33.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
13.12% -6.68% -88.36% -4.80% 4.58% 14.24% -9.94% 14.21% 17.53% 0.00% 0.00%
EBIT Q/Q Growth
13.31% -6.29% -94.20% -4.86% 4.28% 13.74% -9.81% 13.79% 16.74% 0.00% 0.00%
NOPAT Q/Q Growth
13.24% -4.46% -89.04% -7.00% 4.94% 14.52% -9.68% 14.00% 10.37% 0.00% 0.00%
Net Income Q/Q Growth
13.29% -3.07% -112.05% -3.66% 4.49% 13.74% -9.81% 13.79% 16.74% 0.00% 0.00%
EPS Q/Q Growth
20.61% 0.00% -106.52% 59.27% 7.59% 14.00% -3,640.20% 67.36% 26.90% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-19.58% 31.70% -53.48% -9.77% -0.50% 14.01% -17.70% 11.82% 20.29% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
99.24% -205.42% -28.17% -23.40% 0.62% 14.35% -11.47% 20.07% 14.92% 0.00% 0.00%
Invested Capital Q/Q Growth
-17.19% -8.91% -207.32% 53.80% -3.97% -23.56% -5.38% -1.06% -2.41% 0.00% 0.00%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin
-23,845.26% -11,805.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -39.49% 0.00%
Operating Margin
-24,102.31% -14,926.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -38.81% 0.00%
EBIT Margin
-24,081.36% -11,929.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -49.43% 0.00%
Profit (Net Income) Margin
-24,085.05% -11,023.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -49.43% 0.00%
Tax Burden Percent
100.00% 92.40% 100.00% 200.52% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.02% 100.01% 100.00% 200.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-83.61% -123.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
30.94% -103.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
-7.36% 25.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-90.97% -98.51% -163.68% -362.37% -128.59% -148.90% -409.19% -615.23% 102.55% 13.39% 33.08%
Cash Return on Invested Capital (CROIC)
-1.09% -42.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-68.31% -62.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -134.09% 0.00%
Return on Assets (ROA)
-68.32% -57.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -134.09% 0.00%
Return on Common Equity (ROCE)
-90.96% -98.49% -163.66% -362.37% -128.59% -148.90% -409.19% -615.23% 102.55% 13.39% 33.08%
Return on Equity Simple (ROE_SIMPLE)
-147.76% -181.29% -99.31% -109.96% -140.49% -338.00% -298.10% 338.32% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -7.84 -14 -33 -35 -23 -46 -24 -12 -1.73 -4.51
NOPAT Margin
-16,871.62% -10,448.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -27.17% 0.00%
Net Nonoperating Expense Percent (NNEP)
-114.55% -20.82% -55.61% -36.77% -34.36% -40.88% -93.93% -63.85% -224.80% 29.85% 93.00%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 64.48% 9.70% 41.32%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
4,227.33% 2,141.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 82.56% 0.00%
R&D to Revenue
6,091.25% 2,910.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 56.25% 0.00%
Operating Expenses to Revenue
24,202.31% 15,026.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 138.81% 0.00%
Earnings before Interest and Taxes (EBIT)
-18 -8.95 -21 -47 -51 -35 -67 -36 -17 -3.14 -6.00
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -8.85 -21 -47 -50 -33 -65 -35 -16 -2.51 -5.75
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 7.67 10.67 39.81 0.79 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 7.67 10.67 39.81 0.79 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.41 1.14 0.54 -1.18 -0.17 -0.27 -0.08
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.29 0.62 0.54 -0.80 -0.07 0.00 0.00
Financial Leverage
-0.24 -0.25 -0.96 -2.26 -1.14 -1.18 -1.34 -3.20 0.13 -0.20 -0.09
Leverage Ratio
1.33 1.71 1.31 2.35 1.39 1.84 2.20 5.65 -0.69 -0.10 -0.23
Compound Leverage Factor
1.33 1.71 1.31 2.47 1.39 1.84 2.20 5.65 -0.69 -0.10 -0.23
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 29.07% 53.17% 34.89% 667.93% -20.41% -36.57% -9.17%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 8.49% 23.98% 0.00% 212.04% -11.82% -36.57% -9.17%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 20.57% 29.19% 34.89% 455.89% -8.59% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.98% 99.95% 100.00% 0.00% 70.93% 46.83% 65.11% -567.93% 120.41% 136.57% 109.17%
Debt to EBITDA
0.00 0.00 0.00 0.00 -0.30 -0.35 -0.18 -0.36 -0.24 -2.60 -0.17
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.83 0.39 0.47 0.20 -0.15 -2.55 0.66
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 -0.21 -0.19 -0.18 -0.25 -0.10 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 -0.42 -0.50 -0.26 -0.52 -0.32 -3.77 -0.22
Net Debt to NOPAT
0.00 0.00 0.00 0.00 1.17 0.56 0.66 0.29 -0.20 -3.70 0.84
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 -0.30 -0.27 -0.26 -0.36 -0.13 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 0.00 5.03 2.39 -10.91 -23.57 -285.95 0.00 -86.32
Noncontrolling Interest Sharing Ratio
0.01% 0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.79 2.66 7.16 0.00 4.89 2.63 4.37 0.87 0.07 0.11 0.31
Quick Ratio
4.28 2.20 7.03 0.00 4.77 2.51 4.25 0.83 0.05 0.02 0.28
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-0.17 -2.70 -7.73 -30 -36 -26 -41 -15 -9.62 -4.42 -6.22
Operating Cash Flow to CapEx
-5,988.78% 0.00% -6,723.63% -27,394.76% -103,660.53% 0.00% -39,326.97% -48,250.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.71 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.37 0.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
8.89 3.75 -2.79 -5.74 -5.27 -2.88 -8.19 -18 -20 -17 -16
Invested Capital Turnover
0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.34 0.00
Increase / (Decrease) in Invested Capital
-12 -5.14 -6.54 -2.95 0.47 2.39 -5.31 -9.40 -2.48 2.70 1.72
Enterprise Value (EV)
0.00 0.00 0.00 670 345 394 -13 15 5.56 0.00 -3.79
Market Capitalization
0.00 0.00 0.00 720 386 407 18 22 3.08 0.00 0.00
Book Value per Share
$0.75 $0.22 $0.42 $1.22 $0.91 $0.25 $0.26 ($0.12) ($7.19) ($7.74) ($3.79)
Tangible Book Value per Share
$0.39 $0.22 $0.42 $1.22 $0.91 $0.25 $0.26 ($0.12) ($7.19) ($7.74) ($3.79)
Total Capital
12 4.56 21 43 51 22 34 1.88 -19 -18 -11
Total Debt
0.00 0.00 0.00 0.00 15 12 12 13 3.83 6.52 1.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 11 6.38 12 8.56 1.61 0.00 0.00
Net Debt
-3.33 -0.81 -24 -49 -41 -13 -31 -6.93 2.48 6.40 -3.79
Capital Expenditures (CapEx)
0.12 0.00 0.24 0.23 0.04 0.00 0.09 0.07 -0.31 -0.04 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.38 -0.20 -3.07 -6.12 -6.08 -3.43 -9.04 -18 -20 -18 -16
Debt-free Net Working Capital (DFNWC)
2.95 0.61 21 43 50 21 34 1.02 -19 -18 -11
Net Working Capital (NWC)
2.95 0.61 21 43 46 16 34 -2.96 -21 -24 -12
Net Nonoperating Expense (NNE)
5.41 0.43 6.94 14 15 11 21 12 4.95 1.42 1.49
Net Nonoperating Obligations (NNO)
-3.33 -0.81 -24 -49 -41 -13 -31 -6.93 2.53 6.96 -3.76
Total Depreciation and Amortization (D&A)
0.18 0.09 0.71 0.22 0.79 1.15 1.38 1.24 1.07 0.63 0.25
Debt-free, Cash-free Net Working Capital to Revenue
-511.22% -262.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -282.04% 0.00%
Debt-free Net Working Capital to Revenue
3,934.95% 818.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -280.22% 0.00%
Net Working Capital to Revenue
3,934.95% 818.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -382.69% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.31) ($0.42) ($0.27) ($1.45) ($1.34) ($0.86) ($0.95) ($16.65) $0.00 $0.00 ($0.49)
Adjusted Weighted Average Basic Shares Outstanding
20.39M 20.32M 51.41M 35.86M 40.12M 40.21M 86.65M 2.17M 0.00 0.00 12.35M
Adjusted Diluted Earnings per Share
($1.31) ($0.42) ($0.27) ($1.45) ($1.34) ($0.86) ($0.95) ($16.65) $0.00 $0.00 ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding
20.39M 20.32M 51.41M 35.86M 40.12M 40.21M 86.65M 2.17M 0.00 0.00 12.35M
Adjusted Basic & Diluted Earnings per Share
($1.31) ($0.42) ($0.27) ($1.45) ($1.34) ($0.86) ($0.95) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
14.42M 20.32M 23.22M 32.44M 38.06M 40.12M 69.96M 2.17M 0.00 0.00 5.07M
Normalized Net Operating Profit after Tax (NOPAT)
-5.36 -2.60 -14 -33 -35 -21 -46 -24 -12 -1.73 -4.51
Normalized NOPAT Margin
-7,153.01% -3,466.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -27.17% 0.00%
Pre Tax Income Margin
-24,085.05% -11,930.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -49.43% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Eloxx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eloxx Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
2,752,774.00 3,143,390.00 3,143,390.00 3,143,390.00 3,143,390.00 5,071,935.00 7,573,935.00 4,036,459.00
DEI Adjusted Shares Outstanding
2,752,774.00 3,143,390.00 3,143,390.00 3,143,390.00 3,143,390.00 5,071,935.00 7,573,935.00 4,036,459.00
DEI Earnings Per Adjusted Shares Outstanding
-1.30 -0.92 -0.54 -0.60 -0.11 -0.74 -0.59 -1.37
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
53.29% 56.66% 0.00% 0.00% 0.00% -154.38% -137.65% -1,495.10%
EBIT Growth
52.16% 54.25% 0.00% 0.00% 0.00% -119.66% -138.08% -1,479.20%
NOPAT Growth
49.08% 33.18% 0.00% 0.00% 0.00% -210.56% -181.29% -1,988.77%
Net Income Growth
52.16% 54.25% 0.00% 0.00% 0.00% -119.66% -138.08% -1,479.20%
EPS Growth
62.25% 83.56% 0.00% 0.00% 0.00% 82.22% 87.89% 15.52%
Operating Cash Flow Growth
50.33% 64.48% 0.00% 0.00% 0.00% -552.91% -173.19% -149.50%
Free Cash Flow Firm Growth
-107.54% -106.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth
-12.62% -14.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
18.37% 22.51% 0.00% -28.38% 81.65% 0.00% -19.94% -23.16%
EBIT Q/Q Growth
17.25% 19.52% 0.00% -10.65% 81.44% 0.00% -19.93% -23.12%
NOPAT Q/Q Growth
12.15% -10.75% 0.00% -29.46% 81.98% 0.00% -17.26% -33.78%
Net Income Q/Q Growth
17.25% 19.52% 0.00% -10.65% 81.44% 0.00% -19.93% -23.12%
EPS Q/Q Growth
33.16% 63.36% 0.00% -10.65% 81.44% 0.00% -725.00% 25.76%
Operating Cash Flow Q/Q Growth
-66.99% 41.71% 0.00% -245.60% 2.17% 0.00% 12.18% 10.65%
Free Cash Flow Firm Q/Q Growth
78.35% 3.80% 0.00% 0.00% 0.00% 0.00% 10.04% -11.24%
Invested Capital Q/Q Growth
-11.84% -2.41% 0.00% 0.00% 0.00% 0.00% -11.42% 2.22%
Profitability Metrics
- - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
163.66% 102.55% 0.00% 0.00% 0.00% 106.01% -22.94% -38.58%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
163.66% 102.55% 0.00% 0.00% 0.00% 106.01% -22.94% -38.58%
Return on Equity Simple (ROE_SIMPLE)
102.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.55 -2.82 -0.86 -1.11 -0.20 -2.66 -3.12 -4.17
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-17.47% -3.24% 0.00% 0.00% 0.00% -34.46% -4.48% -4.89%
Return On Investment Capital (ROIC_SIMPLE)
- 15.02% - - - 35.03% -6.71% -10.15%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.59 -2.89 -1.71 -1.89 -0.35 -3.75 -4.50 -5.54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.35 -2.60 -1.47 -1.89 -0.35 -3.75 -4.49 -5.54
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 2.03 4.25
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 2.03 4.25
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
-0.27 -0.17 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
-0.13 -0.07 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.48 0.13 0.00 0.00 0.00 0.84 -1.33 -1.37
Leverage Ratio
-1.32 -0.69 0.00 0.00 0.00 -1.12 1.37 1.42
Compound Leverage Factor
-1.32 -0.69 0.00 0.00 0.00 -1.12 1.37 1.42
Debt to Total Capital
-37.24% -20.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
-19.30% -11.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-17.94% -8.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
137.24% 120.41% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.28 -0.24 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
-0.02 -0.15 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.14 -0.10 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.40 -0.32 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-0.03 -0.20 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.19 -0.13 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-71.72 -258.65 0.00 0.00 0.00 -52.49 -2.84 -0.93
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
0.24 0.07 0.00 0.00 0.00 0.53 3.74 3.39
Quick Ratio
0.20 0.05 0.00 0.00 0.00 0.40 3.65 3.27
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
-0.35 -0.34 0.00 0.00 0.00 11 12 11
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - -
Invested Capital
-20 -20 0.00 0.00 0.00 -14 -16 -15
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.20 -2.48 0.00 0.00 0.00 -14 -16 -15
Enterprise Value (EV)
28 5.56 0.00 0.00 0.00 -2.47 32 118
Market Capitalization
28 3.08 0.00 0.00 0.00 3.90 94 175
Book Value per Share
($7.28) ($7.19) $0.00 $0.00 $0.00 ($1.50) $6.13 $10.17
Tangible Book Value per Share
($7.28) ($7.19) $0.00 $0.00 $0.00 ($1.50) $6.13 $10.17
Total Capital
-15 -19 0.00 0.00 0.00 -7.58 46 41
Total Debt
5.44 3.83 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
2.62 1.61 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.45 2.48 0.00 0.00 0.00 -6.37 -62 -56
Capital Expenditures (CapEx)
-0.23 -0.05 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-20 -20 0.00 0.00 0.00 -14 -16 -15
Debt-free Net Working Capital (DFNWC)
-15 -19 0.00 0.00 0.00 -7.58 46 41
Net Working Capital (NWC)
-18 -21 0.00 0.00 0.00 -7.58 46 41
Net Nonoperating Expense (NNE)
1.05 0.07 0.85 0.78 0.15 1.10 1.39 1.38
Net Nonoperating Obligations (NNO)
0.45 2.53 0.00 0.00 0.00 -6.37 -62 -56
Total Depreciation and Amortization (D&A)
0.24 0.29 0.24 0.00 0.00 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
($1.31) ($0.48) $0.00 $0.00 $0.00 ($0.08) ($0.66) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding
2.75M 2.57M 0.00 0.00 0.00 48.21M 6.79M 11.40M
Adjusted Diluted Earnings per Share
($1.31) ($0.48) $0.00 $0.00 $0.00 ($0.08) ($0.66) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding
2.75M 2.57M 0.00 0.00 0.00 48.21M 6.79M 11.40M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
3.14M 0.00 0.00 0.00 0.00 7.57M 4.04M 4.09M
Normalized Net Operating Profit after Tax (NOPAT)
-2.55 -2.82 -0.86 -1.11 -0.20 -2.66 -3.12 -4.17
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Eloxx Pharmaceuticals (NASDAQ:ELOX) ended Q2 2026 with substantially improved liquidity, but the balance-sheet improvement was driven primarily by external financing rather than operating performance. Cash and equivalents rose to $62.0 million from $6.4 million at the end of Q1, while total assets increased to $63.4 million from $8.5 million. The company reported $16.97 million of current liabilities and $46.42 million of equity, compared with negative equity of $7.58 million in Q1.

However, Eloxx continues to report no revenue and remains deeply unprofitable. Q2 operating expenses increased to $4.45 million from $1.58 million in the year-earlier quarter, led by higher research and development spending of $2.84 million. The net loss widened to $4.50 million from $1.89 million in Q2 2025, while operating cash flow was negative $4.79 million. This compares with negative operating cash flow of $1.75 million in Q2 2025 and positive operating cash flow of $1.20 million in Q1 2025, although the earlier positive result was aided by sizable noncash adjustments.

The quarter’s $55.6 million increase in cash came almost entirely from financing: Eloxx raised $53.3 million through common equity issuance and $7.0 million through debt issuance. At the Q2 operating cash-burn rate, the reported cash balance could provide roughly 13 quarters of coverage before considering changes in spending, financing, working capital or other obligations. Investors should treat that estimate cautiously because the company has no reported revenue and its spending has been volatile.

  • Liquidity improved sharply: Cash and equivalents increased by approximately $55.6 million sequentially to $62.0 million at June 30, 2026.
  • Balance-sheet equity turned positive: Total equity improved from negative $7.6 million in Q1 2026 to positive $46.4 million in Q2.
  • Current liabilities remain below current assets: Q2 current assets of $63.4 million exceeded current liabilities of $17.0 million, providing a stronger near-term liquidity position.
  • SG&A declined sequentially: Selling, general and administrative expense fell to $1.61 million in Q2 from $2.14 million in Q1 2026.
  • Financing provides a substantial cash runway: The company’s cash balance is sizeable relative to its recent quarterly operating cash burn, but the runway depends on maintaining spending levels and does not represent internally generated funding.
  • Debt obligations appear limited on the reported balance sheet: No short-term or noncurrent debt was listed at quarter-end, although Q2 cash flow shows a $7.0 million debt issuance that investors should monitor in future filings.
  • Revenue remains absent: Eloxx reported zero revenue in Q1 and Q2 2025 and Q1 and Q2 2026, leaving the company without an operating revenue base.
  • Losses are worsening year over year: The Q2 2026 net loss of $4.50 million was more than double the $1.89 million loss reported in Q2 2025.
  • Operating cash flow remains negative: The company used $4.79 million in operating cash during Q2 2026, following negative operating cash flow of $5.45 million in Q1.
  • Heavy reliance on equity financing creates dilution risk: The $53.3 million common-stock issuance was the primary source of the quarter’s cash increase, while weighted-average basic shares rose to 6.8 million in Q2 2026 from 0.35 million in Q2 2025. Retained earnings also remained deeply negative at $308.8 million.
11/19/26 04:05 PM ETAI Generated. May Contain Errors.

Eloxx Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Eloxx Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Eloxx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$6.00 million in 2025, rising from -$18.06 million in 2015. The previous period was -$3.14 million in 2024. See Eloxx Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Eloxx Pharmaceuticals' total operating income in 2025 was -$6.44 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $6.44 million

Over the last 10 years, Eloxx Pharmaceuticals' total revenue changed from $75 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Eloxx Pharmaceuticals' cash and equivalents has ranged from $4.78 million in Q3 2023 to $61.96 million in Q2 2026, and is currently $56.26 million as of their latest financial filing in Q3 2026.

Eloxx Pharmaceuticals had total debt of $1 million at the end of 2025, a 84.7% decrease from 2024, and none in 2015.

Over the last 10 years, Eloxx Pharmaceuticals' book value per share changed from 0.75 in 2015 to -3.79 in 2025.



Financial statements for NASDAQ:ELOX last updated on 11/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners